NO944919D0 - Fremgangsmåte for å inhibere atrofi av huden eller vagina - Google Patents

Fremgangsmåte for å inhibere atrofi av huden eller vagina

Info

Publication number
NO944919D0
NO944919D0 NO944919A NO944919A NO944919D0 NO 944919 D0 NO944919 D0 NO 944919D0 NO 944919 A NO944919 A NO 944919A NO 944919 A NO944919 A NO 944919A NO 944919 D0 NO944919 D0 NO 944919D0
Authority
NO
Norway
Prior art keywords
vagina
skin
inhibiting atrophy
atrophy
inhibiting
Prior art date
Application number
NO944919A
Other languages
English (en)
Other versions
NO944919L (no
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944919D0 publication Critical patent/NO944919D0/no
Publication of NO944919L publication Critical patent/NO944919L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO944919A 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere atrofi av huden eller vagina NO944919L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,087 US5461064A (en) 1993-12-21 1993-12-21 Methods of inhibiting atrophy of the skin and vagina

Publications (2)

Publication Number Publication Date
NO944919D0 true NO944919D0 (no) 1994-12-19
NO944919L NO944919L (no) 1995-06-22

Family

ID=22622468

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944919A NO944919L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere atrofi av huden eller vagina

Country Status (17)

Country Link
US (2) US5461064A (no)
EP (1) EP0664124B1 (no)
JP (1) JPH07215860A (no)
KR (1) KR950016732A (no)
CN (1) CN1108097A (no)
AU (1) AU699948B2 (no)
CA (1) CA2138511A1 (no)
CZ (1) CZ321594A3 (no)
DE (1) DE69426690T2 (no)
ES (1) ES2153851T3 (no)
HU (1) HUT71221A (no)
IL (1) IL112041A0 (no)
NO (1) NO944919L (no)
NZ (1) NZ270173A (no)
PH (1) PH31600A (no)
RU (1) RU2143897C1 (no)
ZA (1) ZA9410078B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
CA2234060A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6488940B2 (en) * 1997-08-21 2002-12-03 Johnson & Johnson Consumer Companies, Inc. Use of 17-α-estradiol for the treatment of aged or sundamaged skin and/or skin atrophy
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
US6245819B1 (en) * 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
US7906480B2 (en) * 2002-05-23 2011-03-15 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
PT1509215E (pt) * 2002-06-06 2007-01-31 Hormos Medical Ltd Tratamento ou profilaxia da atrofia urogenital e seus sintomas em mulheres
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
US8097660B2 (en) * 2006-08-31 2012-01-17 Bayer Materialscience Llc Rigid polyurethane foams with low thermal conductivity and a process for their production
WO2008039864A1 (en) * 2006-09-26 2008-04-03 Novavax, Inc. Emulsion formulations for transdermal delivery of poorly water soluble active agents
PL2121553T3 (pl) 2007-02-14 2012-11-30 Hormos Medical Ltd Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
US7504530B2 (en) 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
ES2965820T3 (es) * 2015-06-01 2024-04-17 Durga Entpr Llc Composiciones para tratamiento de vaginitis atrófica, dispareunia perimenopáusica y posmenopaúsica y/o mujeres ooforectomizadas y métodos de tratamiento con las mismas
PL3498276T3 (pl) * 2017-12-14 2021-03-08 Ntc S.R.L Zastosowanie ektoiny i pochodnych ektoiny w schorzeniach sromowo-pochwowych

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993010742A2 (en) * 1991-11-27 1993-06-10 Novo Nordisk A/S Chemical compounds, their preparation and use

Also Published As

Publication number Publication date
RU2143897C1 (ru) 2000-01-10
US5461064A (en) 1995-10-24
AU8154294A (en) 1995-06-29
DE69426690D1 (de) 2001-03-22
NO944919L (no) 1995-06-22
CZ321594A3 (en) 1995-09-13
NZ270173A (en) 1996-08-27
IL112041A0 (en) 1995-03-15
HU9403655D0 (en) 1995-02-28
CA2138511A1 (en) 1995-06-22
HUT71221A (en) 1995-11-28
DE69426690T2 (de) 2001-08-09
RU94044436A (ru) 1996-10-20
CN1108097A (zh) 1995-09-13
EP0664124A1 (en) 1995-07-26
KR950016732A (ko) 1995-07-20
AU699948B2 (en) 1998-12-17
JPH07215860A (ja) 1995-08-15
ZA9410078B (en) 1996-06-19
ES2153851T3 (es) 2001-03-16
EP0664124B1 (en) 2001-02-14
US5610167A (en) 1997-03-11
PH31600A (en) 1998-11-03

Similar Documents

Publication Publication Date Title
NO944919D0 (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
AU9040491A (en) Method for the isolation and purification of taxane derivatives
BR9403948A (pt) Composição de matéria
BR9403946A (pt) Composição de matéria
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
AU6847894A (en) Method for the improvement of wound healing and compositions therefor
FI940769A (fi) Menetelmä 2-aminoatsolijohdannaisten valmistamiseksi
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
NO930574L (no) Fremgangsmaate for fremstilling av desfluran
NO990792L (no) FremgangsmÕte for inhibering av ekspresjonen av FAS
FI973095A (fi) Menetelmiä ympäristöestrogeenien estämiseksi
AU1104392A (en) Method for the treatment of hepatic failure and disease
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
DE69314820T2 (de) Chirurgischer Dilator
FI946081A (fi) Steroidaalinen beta-0-sellobiosidihepta-alkanoaattimenetelmä
GB9510162D0 (en) Compositions for the treatment of skin conditions
AU629032B2 (en) Letterpress for transferring and method of transferring by use of the letterpress for transferring
NO990283D0 (no) Formulering for behandling og/eller profylakse av demens
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers
NO964291D0 (no) Fremgangsmåte for behandling av allergisk rinitt
FI932887A0 (fi) Foerbaettrat foerfarande foer framstaellning av 4-nitro-3-trifluorometylanilin
AU1956692A (en) Method for inhibiting the development of body odors
NO933264D0 (no) Framgangsmaate for framstilling av ferrosilisium
SE9300381D0 (sv) Foerfaringssaett vid desinficering av vatten